Romano Di Fabio

This inventor holds 33 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Glaxo Group Limited, Smithkline Beecham Corporation, Glaxo Wellcome Spa. Active years: 1999-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Romano Di Fabio. Retrieved from https://idiyas.com/inventor/romano-di-fabio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 11)

% Patents Active = 33.3

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 143(Granted Patents)

Company Filing History:

Smithkline Beecham Corporation

Neurocrine Biosciences, Inc.

patents

5. 1 out of 4

Chronos Therapeutics Limited

Sb Pharmaco Puerto Rico Inc.

patent

11. 1 out of 6

Sb Pharmco Puerto Rico Inc.

patents

12. 1 out of 10

Smithkline Beecham (Cork) Ltd

patents

13. 1 out of 1

Smithkline Beecham Croporation

patent

where one patent can have more than one assignee

Years Active: 1999-2023

Loading Chart...

Areas of Expertise:

Orexin Receptor Antagonists

Dopamine D3 Receptors

Neurokinin 1 Receptor

Corticotropin Releasing Factor

Tetrahydroquinoline Derivatives

Pyrrolo[1,2-a]Piperazines

Indole Derivatives

Chemical Compounds

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11660293 - Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists (2023-05-30),

2. 9181259 - Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists (2015-11-10),

3. 8263782 - [object Object] (2012-09-11),

4. 8222266 - [object Object] (2012-07-17),

5. 8133908 - Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine (2012-03-13),

6. 8030322 - Spirocompounds useful as modulators for dopamine D3 receptors (2011-10-04),

7. 7855298 - [object Object] (2010-12-21),

8. 7799815 - Triazole derivatives as modulators of dopamine D3 receptors (2010-09-21),

9. 7727988 - Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione (2010-06-01),

10. 7691893 - Chemical compounds (2010-04-06),

11. 7652012 - [object Object] (2010-01-26),

12. 7625904 - Methods for the treatment of sleep disorders (2009-12-01),

13. 7462622 - Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists (2008-12-09),

14. 7446108 - Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists (2008-11-04),

15. 7427630 - Condensed N-heterocyclic compounds and their use as CRF receptor antagonists (2008-09-23),

Title: Romano Di Fabio - Innovative Inventor from Verona

Introduction: Romano Di Fabio is a renowned inventor hailing from the picturesque city of Verona, Italy. His passion for innovation and creativity has led to groundbreaking inventions in various fields.

Latest Patents: Romano Di Fabio holds several recent patents in the fields of renewable energy, sustainable agriculture, and advanced materials. His innovative solutions have garnered attention for their practicality and efficiency.

Career Highlights: With a career spanning over two decades, Romano Di Fabio has established himself as a leading figure in the world of inventors. His dedication to pushing the boundaries of technology has resulted in numerous successful ventures and patents.

Collaborations: Throughout his career, Romano Di Fabio has collaborated with top research institutions, universities, and companies worldwide. His ability to work in multidisciplinary teams has led to the development of cutting-edge technologies with real-world applications.

Conclusion: Romano Di Fabio's relentless pursuit of innovation and his commitment to creating solutions for global challenges make him a standout figure in the world of inventors. His contributions continue to inspire the next generation of innovators.

Profile summary based on public USPTO records.